157 related articles for article (PubMed ID: 36493798)
1. Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with
Bewersdorf JP; Patel KK; Goshua G; Shallis RM; Podoltsev NA; Stahl M; Stein EM; Huntington SF; Zeidan AM
Leuk Lymphoma; 2023 Feb; 64(2):454-461. PubMed ID: 36493798
[TBL] [Abstract][Full Text] [Related]
2. Comparison of venetoclax and ivosidenib/enasidenib for unfit newly diagnosed patients with acute myeloid leukemia and
Wang L; Song J; Xiao X; Li D; Liu T; He X
J Chemother; 2024 May; 36(3):202-207. PubMed ID: 37599456
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective.
Pratz KW; Chai X; Xie J; Yin L; Nie X; Montez M; Iantuono E; Downs L; Ma E
Pharmacoeconomics; 2022 Aug; 40(8):777-790. PubMed ID: 35696071
[TBL] [Abstract][Full Text] [Related]
4. Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost-Utility Analysis.
Guinan K; Mathurin K; Au Y; Schuh AC; Bui CN; Chai X; Lachaine J
Curr Oncol; 2022 Oct; 29(10):7524-7536. PubMed ID: 36290869
[TBL] [Abstract][Full Text] [Related]
5. Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.
Tikhonova IA; Hoyle MW; Snowsill TM; Cooper C; Varley-Campbell JL; Rudin CE; Mujica Mota RE
Pharmacoeconomics; 2017 Mar; 35(3):363-373. PubMed ID: 27752999
[TBL] [Abstract][Full Text] [Related]
6. FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation.
Woods A; Norsworthy KJ; Wang X; Vallejo J; Chiu Yuen Chow E; Li RJ; Sun J; Charlab R; Jiang X; Pazdur R; Theoret MR; de Claro RA
Clin Cancer Res; 2024 Apr; 30(7):1226-1231. PubMed ID: 38010220
[TBL] [Abstract][Full Text] [Related]
7. Ivosidenib and Azacitidine in
Montesinos P; Recher C; Vives S; Zarzycka E; Wang J; Bertani G; Heuser M; Calado RT; Schuh AC; Yeh SP; Daigle SR; Hui J; Pandya SS; Gianolio DA; de Botton S; Döhner H
N Engl J Med; 2022 Apr; 386(16):1519-1531. PubMed ID: 35443108
[TBL] [Abstract][Full Text] [Related]
8. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are not eligible to receive intensive induction chemotherapy in Canada.
Hu Y; Charaan M; van Oostrum I; Heeg B; Bell T
J Med Econ; 2021; 24(1):150-161. PubMed ID: 33461352
[TBL] [Abstract][Full Text] [Related]
10. Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.
DiNardo CD; Stein AS; Stein EM; Fathi AT; Frankfurt O; Schuh AC; Döhner H; Martinelli G; Patel PA; Raffoux E; Tan P; Zeidan AM; de Botton S; Kantarjian HM; Stone RM; Frattini MG; Lersch F; Gong J; Gianolio DA; Zhang V; Franovic A; Fan B; Goldwasser M; Daigle S; Choe S; Wu B; Winkler T; Vyas P
J Clin Oncol; 2021 Jan; 39(1):57-65. PubMed ID: 33119479
[TBL] [Abstract][Full Text] [Related]
11. A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies.
Lachowiez CA; Loghavi S; Zeng Z; Tanaka T; Kim YJ; Uryu H; Turkalj S; Jakobsen NA; Luskin MR; Duose DY; Tidwell RSS; Short NJ; Borthakur G; Kadia TM; Masarova L; Tippett GD; Bose P; Jabbour EJ; Ravandi F; Daver NG; Garcia-Manero G; Kantarjian H; Garcia JS; Vyas P; Takahashi K; Konopleva M; DiNardo CD
Blood Cancer Discov; 2023 Jul; 4(4):276-293. PubMed ID: 37102976
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia.
Patel KK; Zeidan AM; Shallis RM; Prebet T; Podoltsev N; Huntington SF
Blood Adv; 2021 Feb; 5(4):994-1002. PubMed ID: 33591323
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of azacitidine maintenance therapy in patients with acute myeloid leukemia.
Zhu J; Wu Q; Wang J; Niu T
Expert Rev Hematol; 2022 Apr; 15(4):375-382. PubMed ID: 35437111
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
[TBL] [Abstract][Full Text] [Related]
15. Ivosidenib and Azacitidine in IDH1-Mutated AML.
Goodman AM; Mohyuddin GR; Prasad V
N Engl J Med; 2022 Jun; 386(26):2536. PubMed ID: 35767449
[No Abstract] [Full Text] [Related]
16. Ivosidenib and Azacitidine in IDH1-Mutated AML.
Gil-Sierra MD; Briceño-Casado MP; Sierra-Sanchez JF
N Engl J Med; 2022 Jun; 386(26):2535-2536. PubMed ID: 35767448
[No Abstract] [Full Text] [Related]
17. Ivosidenib and Azacitidine in IDH1-Mutated AML. Reply.
Montesinos P; de Botton S; Döhner H
N Engl J Med; 2022 Jun; 386(26):2536-2537. PubMed ID: 35767450
[No Abstract] [Full Text] [Related]
18. Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States.
Stein E; Xie J; Duchesneau E; Bhattacharyya S; Vudumula U; Ndife B; Bonifacio G; Guerin A; Li N; Joseph G
Pharmacoeconomics; 2019 Feb; 37(2):239-253. PubMed ID: 30382485
[TBL] [Abstract][Full Text] [Related]
19. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
DiNardo CD; Schuh AC; Stein EM; Montesinos P; Wei AH; de Botton S; Zeidan AM; Fathi AT; Kantarjian HM; Bennett JM; Frattini MG; Martin-Regueira P; Lersch F; Gong J; Hasan M; Vyas P; Döhner H
Lancet Oncol; 2021 Nov; 22(11):1597-1608. PubMed ID: 34672961
[TBL] [Abstract][Full Text] [Related]
20. Is Induction of Hypomethylation with Ivosidenib and 5-Azacitidine Curative Regimen against IDH1-Mutated Acute Myeloid Leukemia?
Takahashi K
Anticancer Agents Med Chem; 2023; 23(8):864-866. PubMed ID: 36503457
[No Abstract] [Full Text] [Related]
[Next] [New Search]
